Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BLCO

BLCO - Bausch + Lomb Corporation Stock Price, Fair Value and News

$16.77-0.07 (-0.42%)
Market Closed

56/100

BLCO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

56/100

BLCO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$18.13

Target 3M

$17.27

Target 6M

$17.54

BLCO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BLCO Price Action

Last 7 days

-2.8%

Last 30 days

-2.2%

Last 90 days

10.8%

Trailing 12 Months

-3.7%

BLCO RSI Chart

BLCO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BLCO Valuation

Market Cap

5.9B

Price/Earnings (Trailing)

-19.47

Price/Sales (Trailing)

1.19

EV/EBITDA

20.73

Price/Free Cashflow

-30.3

BLCO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$18.13

Target 3M

$17.27

Target 6M

$17.54

BLCO Fundamentals

BLCO Revenue

Revenue (TTM)

5.0B

Rev. Growth (Yr)

7.11%

Rev. Growth (Qtr)

0.23%

BLCO Earnings

Earnings (TTM)

-305.0M

Earnings Growth (Yr)

-800%

Earnings Growth (Qtr)

54.84%

BLCO Profitability

EBT Margin

-6.83%

Return on Equity

-4.74%

Return on Assets

-2.21%

Free Cashflow Yield

-3.3%

BLCO Investor Care

Shares Dilution (1Y)

0.58%

Diluted EPS (TTM)

-0.86

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20254.8B4.9B5.0B0
20244.3B4.5B4.7B4.8B
20233.8B3.9B4.0B4.1B
20223.8B3.8B3.8B3.8B
20213.5B3.6B3.7B3.8B
20200003.4B
Get all data in R, Python etc through our Historical Stock Data APIs

About Bausch + Lomb Corporation

BLCO
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
 CEO
 WEBSITEbausch.com
 SECTORHealthcare
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES13000

Bausch + Lomb Corporation Frequently Asked Questions

BLCO is the stock ticker symbol of Bausch + Lomb Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Bausch + Lomb Corporation is 5.94 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BLCO's fair value in chart for subscribers.

The fair value guage provides a quick view whether BLCO is over valued or under valued. Whether Bausch + Lomb Corporation is cheap or expensive depends on the assumptions which impact Bausch + Lomb Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BLCO.

As of Wed Jan 28 2026, BLCO's PE ratio (Price to Earnings) is -19.47 and Price to Sales (PS) ratio is 1.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLCO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Bausch + Lomb Corporation has provided 0.112 (multiply by 100 for percentage) rate of return.